WallStSmart
ABBV

AbbVie Inc

NYSE: ABBV · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$211.32
+3.64% today

Updated 2026-04-29

Market cap
$360.63B
P/E ratio
99.95
P/S ratio
5.90x
EPS (TTM)
$2.04
Dividend yield
—
52W range
$171 – $239
Volume
6.9M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

AbbVie Inc (ABBV) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$211.32
Consensus
$251.00
+18.78%
2030 Target
$218.58
+3.44%
DCF
$163.42
-29.31% MoS
35 analysts:
9 Buy5 Hold0 Sell

Management guidance

AbbVie has not provided specific CEO revenue guidance for 2026-2030 in the available materials. However, the company announced a $1.4B manufacturing investment in North Carolina (largest capital investment to date) and committed to $100B in U.S. R&D and capital investments over the next decade, signaling confidence in sustained growth. The company's immunology drugs (Skyrizi, Rinvoq) have already exceeded 2027 revenue guidance, demonstrating strong execution.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$337.81
$94.3B Rev × 6.4x P/S
Base case (2030)
$218.58
$94.3B Rev × 4x P/S
Bear case (2030)
$119.23
$94.3B Rev × 2.4x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$54.3B$56.3B$61.2B$68.4B$74.0B$80.1B$87.0B$94.3B
Revenue growth—3.7%8.6%11.9%8.1%8.3%8.5%8.4%
EPS$11.11$10.12$10.00$14.83$16.41$18.10$19.95$21.80
P/S ratio———4.0x4.0x4.0x4.0x4.0x
Implied price———$158.97$158.97$178.84$198.71$218.58

Catalysts & risks

Growth catalysts
+ Skyrizi and Rinvoq immunology franchise expansion driving baseline growth beyond 2027 guidance
+ $1.4B Durham manufacturing campus (operational by late 2028) supporting oncology, neuroscience, and immunology pipeline
+ Obesity/GLP-1 program (ABBV-295) showing positive Phase 1 data; significant market opportunity if successful
+ TrenibotE manufacturing issue resolution (FDA CRL non-safety related) could unlock aesthetics revenue by 2027
+ Late-stage pipeline advancement in ovarian cancer (mirvetuximab), pain management (Haisco deal), and neurological diseases
Key risks
- TrenibotE FDA rejection delays aesthetic revenue contribution; aesthetics segment already facing headwinds in 2026
- Competitive oral psoriasis treatments emerging (UCB's Bimzelx, J&J offerings) pressuring Skyrizi pricing and market share
- Patent cliff executed (Humira), but execution risk on new franchises to sustain growth
- Regulatory and pricing pressure on key products from governments (Trump administration drug import tariffs, international price controls)
- Obesity program (ABBV-295) still in Phase 1; significant development risk and timeline uncertainty

Methodology

AbbVie Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 35 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 25, 2026.